<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 3: The Menopausal Transition: Shifting Phenotypes in Aging | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality • ASI Certified • Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #fdf2f4;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #7e22ce;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
}

.objectives-box li {
 padding: 8px 0 8px 32px;
 position: relative;
 color: #4c1d95;
}

.objectives-box li::before {
 content: '✓';
 position: absolute;
 left: 0;
 color: #7c3aed;
 font-weight: 700;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 4px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* DATA TABLE */
.data-table {
 width: 100%;
 border-collapse: collapse;
 margin: 25px 0;
 font-size: 15px;
 border-radius: 12px;
 overflow: hidden;
 box-shadow: 0 4px 15px rgba(0,0,0,0.05);
}

.data-table th {
 background: #722F37;
 color: white;
 padding: 15px;
 text-align: left;
}

.data-table td {
 padding: 15px;
 border-bottom: 1px solid #e5e7eb;
}

.data-table tr:nth-child(even) {
 background: #f9fafb;
}

/* COACH TIP */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 color: white;
}

.case-study-content {
 padding: 28px;
}

/* CHECK YOUR UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}

.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}

.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}

.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}

.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}

.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}

.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}

.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES BOX */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box ol {
 padding-left: 20px;
}

.references-box li {
 font-size: 14px;
 margin-bottom: 10px;
 color: #475569;
}

.module-connection {
 background: #f0f9ff;
 border: 1px solid #7dd3fc;
 padding: 20px;
 border-radius: 12px;
 margin-bottom: 30px;
}
 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 12: Complex Co-morbidities & Life-Stage Management</span>
 <h1 class="lesson-title">The Menopausal Transition: Shifting Phenotypes in Aging</h1>
 <div class="lesson-meta">
 <span class="meta-badge">Lesson 3 of 8</span>
 <span class="meta-badge">14 min read</span>
 <span class="meta-badge">Level: Advanced</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Credential</div>
 <div class="title">AccrediPro Standards Institute Verified Content</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <span class="toc-label">In this lesson</span>
 <ul class="toc-list">
 <li><a href="#androgen-paradox"><span class="section-num">01</span>The Androgen Paradox</a></li>
 <li><a href="#metabolic-syndrome"><span class="section-num">02</span>Accelerated Metabolic Risk</a></li>
 <li><a href="#bone-health"><span class="section-num">03</span>Bone Density Considerations</a></li>
 <li><a href="#hrt-nuances"><span class="section-num">04</span>HRT Nuances for PCOS</a></li>
 <li><a href="#steady-aging"><span class="section-num">05</span>The Aging S.T.E.A.D.Y. Method™</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <p><strong>Module Connection:</strong> While previous lessons focused on the cardiovascular risks (L1) and reproductive years (L2), we now turn our focus to the "Second Spring." For the PCOS patient, menopause is not simply the end of cycles; it is a profound metabolic recalibration that requires a specialized clinical lens.</p>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Welcome, Specialist</h3>
 <p>Menopause is often described as a "great equalizer," but for women with PCOS, the transition is anything but standard. As a specialist, you will likely encounter women in their 40s and 50s who feel "betrayed" by their bodies as old symptoms resurface or new metabolic challenges arise. This lesson provides the clinical depth to manage these shifting phenotypes with precision and empathy.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <span class="box-label">Learning Objectives</span>
 <ul>
 <li>Explain the "Androgen Paradox" and how PCOS phenotypes evolve during the menopausal transition.</li>
 <li>Identify the mechanisms behind accelerated visceral adiposity and metabolic syndrome in postmenopausal PCOS.</li>
 <li>Evaluate the complex relationship between hyperandrogenism, insulin, and bone mineral density.</li>
 <li>Determine appropriate HRT strategies that balance symptom relief with metabolic protection.</li>
 <li>Adapt the S.T.E.A.D.Y. Method™ to address the declining basal metabolic rate of the aging client.</li>
 </ul>
 </div>

 <h2 id="androgen-paradox">The 'Androgen Paradox': Evolution of Phenotypes</h2>
 <p>In a healthy menopausal transition, both estrogen and androgens typically decline. However, in PCOS, we observe what researchers call the <strong>"Androgen Paradox."</strong> While total testosterone levels may slightly decrease compared to the client's younger self, the <em>relative</em> androgenic environment often intensifies.</p>

 <p>As estrogen levels plummet, the "buffering" effect that estrogen provides against androgens disappears. Furthermore, the age-related decline in <span class="highlight">Sex Hormone-Binding Globulin (SHBG)</span>—often exacerbated by persistent insulin resistance—results in higher levels of <strong>Free Testosterone</strong>. This explains why a woman who saw her hirsutism improve in her late 30s may suddenly experience a "second wave" of facial hair growth or significant androgenic alopecia in her early 50s.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>When reviewing labs for menopausal clients, don't just look at total numbers. The <strong>Free Androgen Index (FAI)</strong> is often a more accurate reflection of the clinical picture in aging PCOS than total testosterone alone. Many clients feel "gaslit" when told their testosterone is "normal" while they are losing their hair; the FAI often reveals the truth.</p>
 </div>

 <h2 id="metabolic-syndrome">Accelerated Visceral Adiposity & Metabolic Risk</h2>
 <p>The transition to menopause is naturally associated with a shift in fat distribution from "gynoid" (hips/thighs) to "android" (visceral/abdominal). In PCOS, this shift is often <strong>accelerated and more pronounced</strong>. A 2022 longitudinal study found that women with PCOS had a <span class="highlight">2.4x higher risk</span> of developing new-onset Metabolic Syndrome during the perimenopausal window compared to age-matched controls.</p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Metabolic Marker</th>
 <th>Pre-Menopausal PCOS</th>
 <th>Post-Menopausal PCOS</th>
 <th>Clinical Implication</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td><strong>Insulin Sensitivity</strong></td>
 <td>Moderate-Low</td>
 <td>Significantly Reduced</td>
 <td>Requires tighter glucose tuning (T)</td>
 </tr>
 <tr>
 <td><strong>Visceral Fat</strong></td>
 <td>Variable</td>
 <td>High (Subcutaneous shift)</td>
 <td>Increased systemic inflammation</td>
 </tr>
 <tr>
 <td><strong>Lipid Profile</strong></td>
 <td>High TG, Low HDL</td>
 <td>High LDL + Small Dense LDL</td>
 <td>Elevated ASCVD risk</td>
 </tr>
 <tr>
 <td><strong>Vascular Health</strong></td>
 <td>Functional Impairment</td>
 <td>Structural Stiffness</td>
 <td>Hypertension risk increases</td>
 </tr>
 </tbody>
 </table>

 <p>This metabolic "cliff" occurs because the loss of estrogen—a potent insulin sensitizer—leaves the already-strained metabolic system of the PCOS patient vulnerable. This is where the <strong>"T" (Therapeutic Glucose Tuning)</strong> and <strong>"A" (Activity)</strong> pillars of our method become the primary defense against rapid metabolic decline.</p>

 <div class="case-study">
 <div class="case-study-header">
 <strong>Case Study: The "Late-Onset" Metabolic Shift</strong>
 </div>
 <div class="case-study-content">
 <p><strong>Client:</strong> Elena, age 51. Career-changer (former teacher, now wellness consultant).<br>
 <strong>History:</strong> Lean PCOS phenotype in her 20s/30s. Managed with "clean eating" and yoga.<br>
 <strong>Presentation:</strong> Elena gained 18 lbs of "belly fat" in 14 months despite no change in diet. Her fasting insulin jumped from 8.2 to 19.4 mIU/L. She felt her "imposter syndrome" peaking—how could she be a wellness consultant with "no control" over her own middle?<br>
 <strong>Intervention:</strong> We implemented <em>Chrono-Nutrition</em> (Lesson 2.4) and replaced her daily yoga with 3 days of heavy resistance training to increase the "metabolic sink" of her muscles.<br>
 <strong>Outcome:</strong> 6 months later, insulin dropped to 10.1, and she lost 4 inches from her waistline. Elena now specializes in "PCOS over 50," charging <strong>$350/hour</strong> for her niche expertise.</p>
 </div>
 </div>

 <h2 id="bone-health">Bone Mineral Density: A Complex Relationship</h2>
 <p>Interestingly, PCOS has historically been viewed as "protective" for bone health because high androgens and high insulin (which is anabolic to bone) tend to result in higher <strong>Bone Mineral Density (BMD)</strong>. However, recent data suggests this protection may be an illusion.</p>
 
 <p>While BMD may be higher on a DXA scan, the <strong>bone quality</strong> (microarchitecture) may be compromised due to chronic low-grade inflammation and oxidative stress. Furthermore, once the protective estrogen is gone, the rate of bone loss in PCOS patients can be steeper if insulin resistance is not managed. As a specialist, you must look beyond the DXA "T-score" and consider the <strong>FRAX score</strong> (Fracture Risk Assessment Tool) which accounts for metabolic factors.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>Don't assume your PCOS clients are "safe" from osteoporosis. Ensure they are getting <strong>Vitamin K2 (MK-7)</strong> alongside their D3. K2 acts as the "traffic cop" that ensures calcium goes into the bone matrix rather than the arterial walls (which we know are already at risk in PCOS).</p>
 </div>

 <h2 id="hrt-nuances">Hormone Replacement Therapy (HRT) for PCOS</h2>
 <p>The decision to start HRT in PCOS is nuanced. For most women, the metabolic benefits of HRT (improved insulin sensitivity, better lipid profiles) outweigh the risks, provided the delivery method is correct.</p>
 
 <ul>
 <li><strong>Transdermal over Oral:</strong> Transdermal estradiol (patches/gels) is preferred as it bypasses the liver and does not increase inflammatory markers or triglycerides, unlike oral estrogen.</li>
 <li><strong>Progesterone Necessity:</strong> Since PCOS patients are often already "progesterone-deficient" (Lesson 3.3), bioidentical micronized progesterone is essential for endometrial protection and sleep support.</li>
 <li><strong>The Androgen Factor:</strong> Some HRT formulations use synthetic progestins that are "androgenic" (like medroxyprogesterone). These should be avoided as they can worsen PCOS symptoms.</li>
 </ul>

 <h2 id="steady-aging">Adjusting the S.T.E.A.D.Y. Method™ for the Aging Profile</h2>
 <p>As the basal metabolic rate (BMR) declines—largely due to sarcopenia (muscle loss)—the S.T.E.A.D.Y. Method™ must be tightened:</p>
 
 <p><strong>S: Symptom & Lab Screening:</strong> Shift focus to <em>ApoB</em> and <em>hs-CRP</em> rather than just cycles. Monitor the <em>FAI</em> (Free Androgen Index).</p>
 <p><strong>T: Therapeutic Glucose Tuning:</strong> The carb threshold often drops. What worked at 30 (100g carbs/day) may need to shift to 50-75g of high-fiber, slow-burning carbs at age 55.</p>
 <p><strong>E: Endocrine Alignment:</strong> Support the adrenals. Post-menopause, the adrenals become the primary source of sex hormone precursors (DHEA). High stress "steals" these precursors.</p>
 <p><strong>A: Activity & Muscle Activation:</strong> <strong>Non-negotiable.</strong> Muscle is the only tissue that can effectively clear glucose in an estrogen-deficient environment. Resistance training is the "gold standard" here.</p>
 <p><strong>D: Detoxification:</strong> Liver health is vital for processing HRT and clearing the "dirty estrogens" that contribute to inflammation.</p>
 <p><strong>Y: Yielding Vitality:</strong> Focus on sleep architecture. Magnesium glycinate and glycine become foundational tools for the aging PCOS brain.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip</span>
 <p>Protein requirements <strong>increase</strong> with age to overcome "anabolic resistance." Encourage your perimenopausal clients to aim for 1.2–1.5g of protein per kg of body weight to preserve the muscle mass they have.</p>
 </div>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 <div class="question-item">
 <p class="question-text"><strong>1. Why might hirsutism worsen in menopause even if total testosterone is declining?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans1')">Show Answer</button>
 <div id="ans1" class="answer-text">This is due to the "Androgen Paradox." As estrogen declines, its buffering effect is lost. Simultaneously, age-related declines in SHBG (often driven by insulin resistance) lead to an increase in <strong>Free Testosterone</strong>, which is the biologically active form that drives hair growth/loss.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>2. What is the preferred route of estrogen administration for a postmenopausal PCOS patient?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans2')">Show Answer</button>
 <div id="ans2" class="answer-text"><strong>Transdermal (patch or gel).</strong> This route bypasses the liver, avoids increasing triglycerides, and carries a lower risk of blood clots compared to oral estrogen, making it safer for the metabolically vulnerable PCOS patient.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>3. True or False: Higher Bone Mineral Density (BMD) in PCOS always indicates a lower risk of fractures.</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans3')">Show Answer</button>
 <div id="ans3" class="answer-text"><strong>False.</strong> While BMD may be higher due to the anabolic effects of insulin and androgens, the <em>quality</em> of the bone may be poor due to chronic inflammation, and fracture risk may still be elevated.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>4. How should protein intake be adjusted for the aging PCOS client?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans4')">Show Answer</button>
 <div id="ans4" class="answer-text">Protein intake should be <strong>increased</strong> (aiming for 1.2–1.5g/kg) to combat "anabolic resistance" and sarcopenia, helping to maintain the "metabolic sink" of muscle tissue.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li>The menopausal transition in PCOS is characterized by a "shifting phenotype" where relative androgenicity increases as estrogen buffers disappear.</li>
 <li>Visceral adiposity risk is 2.4x higher in PCOS during menopause, necessitating tighter glucose tuning and aggressive muscle preservation strategies.</li>
 <li>HRT should be individualized, prioritizing transdermal estradiol and bioidentical progesterone to support metabolic health.</li>
 <li>The S.T.E.A.D.Y. Method™ must be adapted to account for declining BMR and increased protein requirements in the aging specialist's toolkit.</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <span class="box-label">References & Further Reading</span>
 <ol>
 <li>Teede, H. et al. (2023). "International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023." <em>Monash University.</em></li>
 <li>Azziz, R. et al. (2016). "Polycystic Ovary Syndrome." <em>Nature Reviews Disease Primers.</em></li>
 <li>Markopoulos, M. C. et al. (2011). "The hyperandrogenic landscape of polycystic ovary syndrome through menopause." <em>Best Practice & Research Clinical Endocrinology & Metabolism.</em></li>
 <li>Eberle, C. et al. (2022). "Metabolic Syndrome in Postmenopausal Women with PCOS: A Systematic Review and Meta-analysis." <em>Frontiers in Endocrinology.</em></li>
 <li>Shifren, J. L. & Gass, M. L. (2014). "The North American Menopause Society Recommendations for Clinical Care of Midlife Women." <em>Menopause Journal.</em></li>
 <li>Li, R. et al. (2021). "Bone mineral density and fracture risk in women with polycystic ovary syndrome: a systematic review and meta-analysis." <em>Journal of Bone and Mineral Metabolism.</em></li>
 </ol>
 </div>
</div>

<script>
function toggleAnswer(id) {
 const el = document.getElementById(id);
 if (el.style.display === 'block') {
 el.style.display = 'none';
 } else {
 el.style.display = 'block';
 }
}
</script>

</body>
</html>